Mayo Clinic to offer CAR T-cell therapy for relapsed non-Hodgkin lymphoma

ROCHESTER, Minn. ? Mayo Clinic announced today that its Rochester campus is one of 16 cancer centers nationally selected to provide chimeric antigen receptor T-cell therapy (CAR T-cell therapy) for adults with?B-cell non-Hodgkin lymphoma?who have not responded to, or have relapsed, after two or more lines of treatment. The therapy, called axicabtagene ciloleucel (Yescarta), is [...]
Source: Mayo Clinic Business News - Category: Pharmaceuticals Source Type: news